TAR-001

N/A

Report date: 2025/01/26 17:10:52
NME

Base Information

Drug NameTAR-001
Drug Alias NameEGFR-targeted synthetic dsRNA therapy (TargImmune)EGFR-targeted Poly-IC therapy (TargImmune)TAR-001
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionReceptor tyrosine-protein kinase erbB modulators
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTargImmune Therapeutics AG
China Registration ClassN/A

Develop Information

Active CompaniesTargImmune Therapeutics AG
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A